| DB ID | MyCo_6190 |
| Title | DIGE enables the detection of a putative serum biomarker of fungal origin in a mouse model of invasive aspergillosis |
| Year | 2012 |
| PMID | 22370163 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Animal |
| Host Common name | Mice |
| Host Scientific name | Mus musculus |
| Biomarker Name | Asp f 2 |
| Biomarker Full Name | Asp f 2 |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | OF1 mice (25 g, 6 week-old) were cared for in accordance with Institut Pasteur guidelines (http://webcampus.pasteur.fr/jcms/c_97153/guidelines) in compliance with the European animal welfare regulation. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is a major threat for immunocom- promised patients. In particular, patients who undergo mye- loablative chemotherapy are especially at risk of developing the disease. Rapid and well-adapted treatment is required to circumvent the disease's high mortality and achieve a favorable outcome. Currently however, diagnosing the disease is difficult and generally based on a body of signs and symp- toms including clinical, radiological and biological features. |
| Technique | Bioinformatics analysis |
| Analysis Method | Proteomics Approach |
| ELISA kits | ProteoMiner kit (Biorad) |
| Assay Data | None |
| Validation Techniques used | Proteomics Approach |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
